Alteogen Inc.

In the past few months, South Korean bioventures, including ABL Bio , have clinched a series of large-scale global out-licensing deals, dominating the transactions in the country so far this year. So

The South Korea government plans to improve the transparency and objectivity of standards for pharma firms to officially qualify as “innovative” and eligible for special policy treatment, amid foreign

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Dr. Reddy’s Acquires Rights From

Merck & Co. is awaiting regulatory approvals for its subcutaneous version of PD-1 inhibitor pembrolizumab, and its successful head-to-head trial against the original intravenous Keytruda (pembroli